-iodobenzylguanidine (IBG) has been radiolabelled at the no-carrier-added level with [I] for a proof of concept study to assess the diagnostic accuracy of [I]IBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of IBG was achieved via the iododesilylation reaction between [I]sodium iodide and -trimethylsilylbenzylguanidine. [I]IBG was produced in 62-70 % radioiodide incorporation yield from [I]sodium iodide. The average amount of formulated [I]IBG was 359 MBq (range 344-389 MBq) with an average specific radioactivity of 4.1 TBq μmol (range 1.8-5.9 TBq μmol) at end of synthesis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219010 | PMC |
| http://dx.doi.org/10.1007/s10967-016-5073-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuroblastoma-derived hypoxic extracellular vesicles promote metastatic dissemination in a zebrafish model.
PLoS One
December 2024
Fondazione Istituto di Ricerca Pediatrica Città della Speranza (IRP), Padova, Italy.
The zebrafish (Danio rerio) is a valuable model organism for studying human biology due to its easy genetic manipulation and small size. It is optically transparent and shares genetic similarities with humans, making it ideal for studying developmental processes, diseases, and drug screening via imaging-based approaches. Solid malignant tumors often contain hypoxic areas that stimulate the release of extracellular vesicles (EVs), lipid-bound structures released by cells into the extracellular space, that facilitate short- and long-range intercellular communication and metastatization.
View Article and Find Full Text PDFCharacterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.
Cancers (Basel)
November 2024
Center for Immuno-Oncology, National Cancer Institute, National Institute of Health, Bethesda, MD 20894, USA.
Olfactory neuroblastoma (ONB), sinonasal undifferentiated carcinoma (SNUC), and sinonasal neuroendocrine carcinoma (SNEC) are rare malignancies arising from the sinonasal tract with limited therapeutic options. The expression of the somatostatin receptor 2 gene (), which is expressed in other neuroendocrine neoplasms and is therapeutically actionable, has been reported in these tumors. Here, we analyzed gene expression and its associations with genomic features, established biomarkers predicting of immune response, and the tumor immune microenvironment in a cohort of ONB, SNUC, and SNEC tumor samples (26, 13, and 8 samples, respectively) from a real-world database.
View Article and Find Full Text PDFUnusually Rapid Isomerization of Aspartic Acid in Tau.
bioRxiv
December 2024
Department of Chemistry, University of California, Riverside, California 92521, United States.
Spontaneous chemical modifications in long-lived proteins can potentially change protein structure in ways that impact proteostasis and cellular health. For example, isomerization of aspartic acid interferes with protein turnover and is anticorrelated with cognitive acuity in Alzheimer's disease. However, few isomerization rates have been determined for Asp residues in intact proteins.
View Article and Find Full Text PDFInvestigating miR-9 and miR-222 in CSF and Plasma of Neuroblastoma Patients as Metastatic and Apoptotic-Related Markers.
Cell Biochem Biophys
December 2024
Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.
Neuroblastoma is a cancer that occurs due to abnormal development of the sympathetic nervous system. The dysregulation of miR-9 and miR-222 plays a crucial role in neuroblastoma development. These microRNAs have a significant relationship with PTEN, caspase-9, and MMP14, which can potentially form the basis for the specific diagnosis and treatment of this disease.
View Article and Find Full Text PDFOtoprotective Effects of Sodium Thiosulfate by Demographic and Clinical Characteristics: A Report From Children's Oncology Group Study ACCL0431.
Pediatr Blood Cancer
December 2024
Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Article Synopsis
- The ACCL0431 trial showed that sodium thiosulfate (STS) effectively reduces cisplatin-induced hearing loss in young patients aged 1-18.
- A secondary analysis revealed that the incidence of hearing loss was significantly lower in those receiving STS (22.4%) compared to those who were only observed (54.0%).
- The best protective effects of STS were seen in younger children (under 5 years) and those with specific cancers like neuroblastoma, indicating the need for tailored treatment strategies based on patient characteristics.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!